Bioventus Inc. BVS
Set alert
13.26 USD -0.06 -0.49%
As of Nov 2, 12:08 PM ET
13.19 Day range 13.73
6.47 52-week range 15.89
- YTD
- +78.23%
- 1 year
- +102.44%
- Open
- 13.52
- Prev close
- 13.33
- Mkt cap
- 905.73M
- Vol
- 143.08K
- Avg vol
- 562.45K
- EPS
- 0.78
- P/E
- 17.00
- Div yield
- 0.00%
More statistics
- Low
- 13.19
- High
- 13.73
- Forward P/E
- 16.16
- Beta
- 0.64
- Short ratio
- 7.53
- Inst. own
- 84.85%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 2, 2026
- 50-d avg
- 13.72
- 200-d avg
- 10.84
- 1y target
- 17.60
2Y chart
Events in this range
- Aug 6, 2025Earnings: 0.21; estimate 0.22; surprise -4.55%
- Nov 4, 2025Earnings: 0.15; estimate 0.215; surprise -30.23%
- Mar 5, 2026Earnings: 0.24; estimate 0.22; surprise 9.09%
- Mar 6, 2026Rating: Barrington Research · Outperform → Outperform
- May 6, 2026Earnings: 0.15; estimate 0.09; surprise 66.67%
- May 22, 2026Rating: Barrington Research · Outperform → Outperform
- Jun 16, 2026Rating: Canaccord Genuity · Buy → Buy
- Jun 30, 2026Rating: Barrington Research · Outperform → Outperform
- Aug 5, 2026Earnings: 0.22; estimate 0.2163; surprise 1.71%
- Aug 17, 2026Rating: Cantor Fitzgerald · Overweight → Overweight
- Aug 17, 2026Rating: Canaccord Genuity · Buy → Buy
- Nov 2, 2026Earnings: —; estimate 0.1496; surprise —%
Signals (94)
| Name | Date | Ago |
|---|---|---|
| MACD: Sell Signal | Nov 2, 2026 | 2 hours ago |
| SMA: Bearish | Oct 30, 2026 | 3 days ago |
| SMA: Bullish | Oct 20, 2026 | 1 week ago |
| SMA: Bearish | Oct 16, 2026 | 2 weeks ago |
| SMA: Bullish | Oct 15, 2026 | 2 weeks ago |
| MACD: Buy Signal | Oct 14, 2026 | 2 weeks ago |
| MACD: Sell Signal | Oct 2, 2026 | 1 month ago |
| SMA: Bearish | Oct 1, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 25, 2026 | 1 month ago |
| SMA: Bullish | Sep 22, 2026 | 1 month ago |
| SMA: Bearish | Sep 10, 2026 | 1 month ago |
| MACD: Sell Signal | Aug 12, 2026 | 2 months ago |
| RSI: Overbought | Aug 5, 2026 | 2 months ago |
| RSI: Overbought | Aug 3, 2026 | 3 months ago |
| MACD: Buy Signal | Jul 28, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 22, 2026 | 3 months ago |
| RSI: Overbought | Jul 13, 2026 | 3 months ago |
| RSI: Overbought | Jul 6, 2026 | 3 months ago |
| SMA: Bullish | Jul 1, 2026 | 4 months ago |
| SMA: Bearish | Jun 30, 2026 | 4 months ago |
| SMA: Bullish | Jun 25, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 16, 2026 | 4 months ago |
| MACD: Sell Signal | Jun 12, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 10, 2026 | 4 months ago |
| SMA: Bullish | Jun 2, 2026 | 5 months ago |
| SMA: Bearish | Jun 1, 2026 | 5 months ago |
| RSI: Oversold | Jun 1, 2026 | 5 months ago |
| SMA: Bearish | May 21, 2026 | 5 months ago |
| MACD: Sell Signal | May 21, 2026 | 5 months ago |
| MACD: Buy Signal | May 20, 2026 | 5 months ago |
| MACD: Sell Signal | May 12, 2026 | 5 months ago |
| MACD: Buy Signal | May 5, 2026 | 6 months ago |
| MACD: Sell Signal | Apr 27, 2026 | 6 months ago |
| RSI: Overbought | Apr 15, 2026 | 6 months ago |
| MACD: Buy Signal | Apr 13, 2026 | 6 months ago |
| MACD: Sell Signal | Mar 30, 2026 | 7 months ago |
| MACD: Buy Signal | Mar 24, 2026 | 7 months ago |
| MACD: Sell Signal | Mar 6, 2026 | 8 months ago |
| MACD: Buy Signal | Mar 5, 2026 | 8 months ago |
| MACD: Sell Signal | Mar 4, 2026 | 8 months ago |
| MACD: Buy Signal | Feb 18, 2026 | 8 months ago |
| MACD: Sell Signal | Feb 12, 2026 | 8 months ago |
| MACD: Buy Signal | Feb 2, 2026 | 9 months ago |
| MACD: Sell Signal | Jan 28, 2026 | 9 months ago |
| MACD: Buy Signal | Jan 8, 2026 | 9 months ago |
| SMA: Bullish | Jan 5, 2026 | 10 months ago |
| SMA: Bearish | Jan 2, 2026 | 10 months ago |
| MACD: Sell Signal | Dec 22, 2025 | 10 months ago |
| MACD: Buy Signal | Dec 17, 2025 | 10 months ago |
| SMA: Bullish | Dec 10, 2025 | 10 months ago |
| SMA: Bearish | Dec 5, 2025 | 11 months ago |
| MACD: Sell Signal | Dec 5, 2025 | 11 months ago |
| SMA: Bullish | Nov 25, 2025 | 11 months ago |
| MACD: Buy Signal | Nov 25, 2025 | 11 months ago |
| SMA: Bullish | Nov 21, 2025 | 11 months ago |
| SMA: Bearish | Nov 19, 2025 | 11 months ago |
| MACD: Sell Signal | Nov 18, 2025 | 11 months ago |
| SMA: Bullish | Nov 11, 2025 | 11 months ago |
| SMA: Bullish | Nov 4, 2025 | 12 months ago |
| MACD: Buy Signal | Nov 4, 2025 | 12 months ago |
| MACD: Sell Signal | Oct 31, 2025 | 1 year ago |
| SMA: Bearish | Oct 23, 2025 | 1 year ago |
| SMA: Bullish | Oct 21, 2025 | 1 year ago |
| MACD: Buy Signal | Oct 15, 2025 | 1 year ago |
| SMA: Bearish | Oct 6, 2025 | 1 year ago |
| SMA: Bullish | Oct 3, 2025 | 1 year ago |
| SMA: Bearish | Sep 19, 2025 | 1 year ago |
| SMA: Bullish | Sep 18, 2025 | 1 year ago |
| SMA: Bearish | Sep 16, 2025 | 1 year ago |
| MACD: Sell Signal | Sep 2, 2025 | 1 year ago |
| SMA: Bullish | Aug 6, 2025 | 1 year ago |
| MACD: Buy Signal | Aug 6, 2025 | 1 year ago |
| MACD: Sell Signal | Jul 16, 2025 | 1 year ago |
| SMA: Bearish | Jul 15, 2025 | 1 year ago |
| SMA: Bullish | Jul 1, 2025 | 1 year ago |
| MACD: Buy Signal | May 15, 2025 | 1 year ago |
| MACD: Sell Signal | May 6, 2025 | 1 year ago |
| RSI: Oversold | May 6, 2025 | 1 year ago |
| MACD: Buy Signal | Apr 24, 2025 | 1 year ago |
| RSI: Oversold | Apr 8, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 25, 2025 | 1 year ago |
| MACD: Buy Signal | Mar 19, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 13, 2025 | 1 year ago |
| SMA: Bearish | Mar 12, 2025 | 1 year ago |
| MACD: Buy Signal | Mar 12, 2025 | 1 year ago |
| SMA: Bullish | Mar 11, 2025 | 1 year ago |
| RSI: Oversold | Mar 10, 2025 | 1 year ago |
| MACD: Sell Signal | Feb 18, 2025 | 1 year ago |
| SMA: Bearish | Feb 12, 2025 | 1 year ago |
| SMA: Bullish | Feb 10, 2025 | 1 year ago |
| SMA: Bearish | Feb 7, 2025 | 1 year ago |
| SMA: Bullish | Feb 4, 2025 | 1 year ago |
| MACD: Buy Signal | Jan 17, 2025 | 1 year ago |
| RSI: Oversold | Jan 7, 2025 | 1 year ago |
Key statistics
- Market cap
- 1.02B
- Enterprise value
- 1.28B
- Trailing P/E
- 19.06
- Forward P/E
- 16.16
- PEG ratio
- 1.53
- Price / sales
- 1.75
- Price / book
- 4.44
- EPS (TTM)
- 0.78
- Beta
- 0.64
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 9.36%
- Revenue (TTM)
- 581.85M
- Revenue growth
- 3.80%
- Free cash flow
- 67.76M
- Total cash
- 30.39M
- Total debt
- 263.75M
- Return on equity
- 25.68%
- Shares outstanding
- 68.31M
- Short % of float
- 6.78%
- 50-day average
- 13.72
- 200-day average
- 10.84
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 17.60 +32.7% upside
Now 13.26
- Target (low)
- 15.00
- Target (mean)
- 17.60
- Target (high)
- 19.00
Ratings (0m) 5 5 buy · 0 hold · 0 sell
- Strong buy2
- Buy3
- Hold0
- Sell0
- Strong sell0
Next earnings
Nov 2, 2026
Expected Nov 2, 2026. Consensus EPS estimate 0.16.
Financials — quick view
BVS Revenue — quarterly 153.21M
BVS Net income — quarterly 33.44M
BVS EPS — quarterly 0.49
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 2, 2026 | Sep 27, 2026 | 0.1496 | — | — | — |
| Aug 5, 2026 | Jun 27, 2026 | 0.2163 | 0.22 | 0.00 | +1.71% |
| May 6, 2026 | Mar 28, 2026 | 0.09 | 0.15 | +0.06 | +66.67% |
| Mar 5, 2026 | Dec 31, 2025 | 0.22 | 0.24 | +0.02 | +9.09% |
| Nov 4, 2025 | Sep 27, 2025 | 0.215 | 0.15 | -0.06 | -30.23% |
| Aug 6, 2025 | Jun 28, 2025 | 0.22 | 0.21 | -0.01 | -4.55% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 17, 2026 | Canaccord Genuity | main | Buy | Buy |
| Aug 17, 2026 | Cantor Fitzgerald | reit | Overweight | Overweight |
| Jun 30, 2026 | Barrington Research | main | Outperform | Outperform |
| Jun 16, 2026 | Canaccord Genuity | main | Buy | Buy |
| May 22, 2026 | Barrington Research | main | Outperform | Outperform |
| Mar 6, 2026 | Barrington Research | main | Outperform | Outperform |
About Bioventus Inc.
Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company's product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain, and TalisMann provides stimulation to the targeted peripheral nerve, as well as XCELL PRP System, a benchtop device that processes whole blood to produce high-yield PRP with a 10-minute single-spin cycle. It also offers precision bone resection for patients with degenerative spine conditions and spinal deformities, as well as enables precision ultrasonic neuro and general surgery to address brain tumors and pathologies of the liver and other organs; and bone graft substitutes, including various products that facilitate optimal bone fusion. In addition, the company provides neXus, an ultrasonic surgical system; BoneScalpel, a surgical solution enabling precise cuts in hard tissue; BoneScalpel Access, for bone removal with visualization; SonaStar system, a precise ablation and removal of soft tissue; SonaStar Elite handpiece and accessories; SonicOne, an ultrasonic cleansing and debridement system; Osteoamp, an allograft-derived bone graft for orthopedic, neurosurgical, and reconstructive bone grafting procedures; Signafuse bone graft; Purebone, a natural osteoconductive scaffold; and Reficio demineralized bone matrix. The company's restorative therapies include minimally invasive fracture treatments and rehabilitation products. Its products also include Exogen, an ultrasound bone stimulation system. The company sells its products to healthcare institutions, physicians, patients, distributors and dealers. Bioventus Inc. was founded in 2011 and is headquartered in Durham, North Carolina.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- bioventus.com
News
- Bioventus to Report Third Quarter of Fiscal Year 2026 Financial Results on November 2, 2026
- Bioventus Inc (BVS) Stock Up 3.6% but GF Value Says Overvalued -- GF Score: 63/100
- Comparing Kestra Medical Technologies (NASDAQ:KMTS) & Bioventus (NASDAQ:BVS)
- Reviewing Bioventus (NASDAQ:BVS) & RxSight (NASDAQ:RXST)
- Bioventus: Cash Flow Anchors The Bull Case Beyond A Potential Sale
- Are Medical Stocks Lagging Bioventus (BVS) This Year?
- 4 Healthcare Stocks to Safeguard Your Portfolio as Fed Plans Rate Hike
- Canaccord Genuity Maintains Buy on Bioventus, Raises Price Target to $19
- Cantor Fitzgerald Reiterates Overweight on Bioventus, Maintains $15 Price Target
- Deal Dispatch: Bending Spoons Acquires Airtable, Bain Capital Buys Gong Cha Global, Salad and Go Bankruptcy
Your note
Sign in to keep a note on BVS — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BARTHOLDSON JOHN A | Director and Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Jun 1, 2026 | 7,051,260 |
| CLAYPOOLE ROBERT E. | Chief Executive Officer | Conversion of Exercise of derivative security | Mar 12, 2026 | 135,944 |
| D'ADAMIO ANTHONY | General Counsel | Conversion of Exercise of derivative security | Apr 9, 2026 | 153,655 |
| HAWKINS WILLIAM A III | Director | Conversion of Exercise of derivative security | Jun 1, 2026 | 297,640 |
| LADONE MARY KAY | Director | Conversion of Exercise of derivative security | Jun 1, 2026 | 111,263 |
| NEELS GUIDO J | Director | Conversion of Exercise of derivative security | Jun 1, 2026 | 117,523 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Essex Woodlands Management Inc. | 19.06% | 13,021,324 | 193.63M | Jun 29, 2026 |
| Juniper Investment Company, LLC | 10.16% | 6,939,357 | 103.19M | Jun 29, 2026 |
| Nantahala Capital Management, LLC | 8.78% | 6,000,279 | 89.22M | Jun 29, 2026 |
| Blackrock Inc. | 5.03% | 3,435,914 | 51.09M | Jun 29, 2026 |
| Royce & Associates LP | 2.68% | 1,833,212 | 27.26M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 2.56% | 1,751,678 | 26.05M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| American Century ETF Trust-Avantis U.S. Small Cap Value ETF | 2.58% | 1,760,427 | 26.18M | Sep 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 1.83% | 1,248,896 | 18.57M | Sep 29, 2026 |
| Brown Advisory Funds-Brown Advisory Small-Cap Fundamental Value Fund | 1.81% | 1,239,520 | 18.43M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 1.70% | 1,163,677 | 17.30M | Jun 29, 2026 |
| ROYCE FUND-Royce Small-Cap Opportunity Fund | 1.26% | 858,738 | 12.77M | Jun 29, 2026 |
| OBERWEIS FUNDS-Oberweis Micro-Cap Fund | 1.00% | 684,514 | 10.18M | Jun 29, 2026 |